US39536G1058 - Common Stock - After market: 1.14 +0.03 (+2.7%)
NASDAQ:GRNA (2/3/2023, 7:00:01 PM)-0.01 (-0.89%)
|GICS Sector||Health Care|
|Earnings (Last)||11-09 2022-11-09/amc||Earnings (Next)||N/A N/A|
|Ins Owners||20.57%||Inst Owners||N/A|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Medford, Massachusetts. The company went IPO on 2021-01-14. The firm is focused on Ribonucleic acid (RNA) research, design, and manufacturing for human, animal, and plant health. The firm has developed technology to create high-performing, natural ribonucleic acid (RNA) products to address global sustainability challenges and promote healthier plants, foods, and people. The firm is engaged in the cell-free biomanufacturing platform. This platform enables the making of complex biological molecules nucleic acids, peptides, carbohydrates, and many others which allows manufacturing products at a lower cost than traditional methods using fermentation. The platform is used to develop and commercialize products. The firm's pipeline for plant and animal health includes Colorado potato beetle, Botrytis cinerea, Varroa mites, Fungicides, Grapevine powdery mildew, Fusarium Head Blight (FHB), Lepidoptera, and Powdery mildew.
GREENLIGHT BIOSCIENCES HOLDI
200 Boston Avenue, Suite 3100
The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase...
The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine...
The company reportedly turned down offers to go private.
Here you can normally see the latest stock twits on GRNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.